

ประวัติคณะผู้วิจัย

ประวัติผู้อำนวยการแผนงาน และหัวหน้าโครงการวิจัยที่ 1

แพทย์หญิง อัญชลี อวิหิงสานนท์

ชื่อ (ภาษาไทย) แพทย์หญิงอัญชลี อวิหิงสานนท์ ตำแหน่งทางวิชาการ อาจารย์พิเศษ
(ภาษาอังกฤษ) Anchalee Avihingsanon, MD

เลขหมายบัตรประชาชน 34199 00116195

ภาควิชา สาขาวิชาโรคภูมิแพ้และภูมิคุ้มกัน ภาควิชาอายุศาสตร์ คณะแพทยศาสตร์

จุฬาลงกรณ์มหาวิทยาลัย

โทรศัพท์ 02-652-3040 โทรสาร 02-252-5779 E-mail anchalee.a@hivnat.org

ที่อยู่ปัจจุบัน ศูนย์วิจัยโรคเอดส์ สภากาชาดไทย 104 ถนนราชดำริ ปทุมวัน กรุงเทพมหานคร 10330

โทรศัพท์ 02-254 2566, 086-812-8889

ประวัติการศึกษา

สถาบัน	ระดับการศึกษา	ปีที่ ศึกษา	สาขาวิชา
คณะแพทยศาสตร์ มหาวิทยาลัยขอนแก่น	แพทยศาสตรบัณฑิต	2529-2535	แพทยศาสตร์
โรงพยาบาลจุฬาลงกรณ์ คณะ แพทยศาสตร์จุฬาลงกรณ์ มหาวิทยาลัย	แพทย์ประจำบ้าน สาขาอายุรศาสตร์	2537-2539	อายุรศาสตร์ทั่วไป
โรงพยาบาลจุฬาลงกรณ์ คณะ แพทยศาสตร์จุฬาลงกรณ์ มหาวิทยาลัย	แพทย์ประจำบ้านต่อ ยอดสาขาอายุรศาสตร์ โรคติดเชื้อ	2540-2542	อายุรศาสตร์โรคติดเชื้อ
Beth Israel Medical Center, Boston, MA, USA	Fellowship in Infectious Disease	2543-2545	HIV and metabolic disease

สาขาวิชาที่มีความชำนาญพิเศษ โรคเอดส์, โรคติดเชื้อ

ผลงานตีพิมพ์

1. **Avihingsanon A**, Suankratay C, Tantawichian T, Nuntapisut P. Two cases of Streptococcus suis endocarditis. *Chula Med J* 1999; 43(5):317-325.
2. Nagy GS, Tsiodras S, Martin LD, **Avihingsanon A**, Gavrilu A, Hsu WC, Karchmer AW, Mantzoros CS. Human immunodeficiency virus type 1-related lipodystrophy and lipohypertrophy are associated with serum concentrations of leptin. *Clin Infect Dis.* 2003; 36(6):795-802.
3. **A Avihingsanon**, Y Avihingsanon, P Darnpornprasert, S Kerr' C. Ungsedhapand, C Duncombe, S Ubolyam, K Ruxrungtham, P Phanuphak and HIV-NAT study team:

- High Prevalence of Indinavir-associated Renal Complications in Thai HIV-infected patients. *J Med Assoc Thai* ; 2006; 89:S21-S27.
4. S. Kerr, C. Duncombe, **A. Avihingsanon**, J. Anaworanich, M. Boyd, B. Sopa, D. Cooper, J. Lange, P. Phanuphak, K. Ruxrungtham, and HIV-NAT Study Group. Dyslipidaemia in an Asian Population After Treatment for 2 Years with Protease Inhibitor-containing Regimens. *J Int Assoc Physicians AIDS Care* 2007; 6(1):36-46.
 5. Van der Lugt J, Autar RS, Ubolyam S, Fernandez Garcia E, Sankote J, **Avihingsanon A**, Chuenyam T, Cooper DA, Lange J, Phanuphak P, Wit F, Ruxrungtham K and Burger D on behalf of the HIV-NAT 019 Study Team: Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naïve HIV-1-infected adults. *J Antimicrob Chemother.* 2008; 61 (5):1145-53.
 6. **Avihingsanon A**, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, Gorowara M, Yamada N, Yanai H, Mitarai S, Ishikawa N, Cooper DA, Phanuphak P, Burger D and Ruxrungtham K. Pharmacokinetics and 48 weeks efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-Tuberculosis co-infection receiving highly active antiretroviral therapy and rifampicin. *Antiviral therapy.* 2008; 13(4):529-536.
 7. Matthews GV*, **Avihingsanon A***, Lewin SR, Amin J, Rerknimitr R, Petcharat P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, Ruxrungtham K, Dore GJ¹. A randomised trial of combination Hepatitis B therapy in HIV/HBV coinfecting antiretroviral naïve individuals in Thailand. *Hepatology* 2008;48(4):1062-9
 8. Preiss S, Littlejohn M, Angus P, Thompson A, Desmond P, Lewin S, Sasadeusz J, Matthews G, Dore G, Shaw T, Sozzi V, Yuen L, Lau G, Hui CK, Thio C, **Avihingsanon A**, Ruxrungtham K, Locarnini S and Revill PA. Defective HBV DNA is not associated with disease status, but is reduced by HBV polymerase mutations associated with antiviral resistance. *Hepatology.* 2008 Apr 21;48(3):741-749.
 9. Srisawat N, **Avihingsanon A**, Praditpornsilpa K, Jiamjarasrangsri W, Eiam-Ong S, Avihingsanon Y. A prevalence of posttransplantation cancers compared with cancers in people with human immunodeficiency virus/acquired immunodeficiency syndrome after highly active antiretroviral therapy. *Transplant Proc.* 2008 Oct;40(8):2677-9.
 10. Crane M; Oliver B; Matthews G; **Avihingsanon A**; Ubolyam S; Markovska V; Chang J; Dore GJ; Price P; Visvanathan K; French M; Ruxrungtham K; Lewin SR. Immunopathogenesis of hepatic flare in HIV-Hepatitis B Virus (HBV) co-infected

- individuals following initiation of HBV-active antiretroviral therapy. *J Infect Dis.* 2009 Apr 1;199(7):974-981..
11. **Avihingsanon A**, Van der Lugt J, Kerr SJ, Gorowara M, Chanmano S, Ohata P, Lange J, Cooper DA, Phanuphak P, Burger DM, Ruxrungtham K. A Low Dose of Ritonavir-Boosted Atazanavir (200/100 mg) Provides Adequate Pharmacokinetic Parameters in Thai HIV-1 Infected Adults. *Clin Pharmacol Ther.* 2009 ;85(4):402-8
 12. Lewin SR, Ribeiro R, **Avihingsanon A**, Bowden S, Matthews G, Marks P, Locarnini SA, Ruxrungtham K, Perelson AS, Dore GJ. Viral dynamics of hepatitis B virus (HBV) in HIV-1-HBV co-infected individuals: similar anti-HBV efficacy of lamivudine, tenofovir or combination therapy. *Hepatology* 2009;49:1113-1121.
 13. Walmsley S, **Avihingsanon A**, Slim J, Ward D, Ruxrungtham K, Brunetta J, Bredeek UF, Jayaweera D, Guittari CJ, Larson P, Schutz M, Raffi F. Gemini: a non-inferiority study of saquinavir/ritonavir vs lopinavir/ritonavir as initial HIV-1 therapy in adults. *J Acquir Immune Defic Syndr.* 2009 Feb 12
 14. Chang JJ, Sirivichayakul S, **Avihingsanon A**, Thompson AJ, Revill P, Iser D, Slavin J, Buranapraditkun S, Marks P, Matthews G, Cooper DA, Kent SJ, Cameron PU, Sasadeusz J, Desmond P, Locarnini S, Dore GJ, Ruxrungtham K, Lewin SR. Impaired quality of the HBV-specific T-cell response in HIV-1-HBV co-infection. *J Virol.* 2009; 83(15):7649-58.
 15. van der Lugt J, Gorowara M, **Avihingsanon A**, Burger D, Ananworanich J, Sringam K, Kerr S, Wit F, Lange J, Ruxrungtham K. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals. *AIDS.* 2009 Jun 1;23(9):1176-9
 16. Li AH, Phanuphak N, Sahasrabuddhe WV, Chaithongwongwatthana S, Vermund SH, Jenkins CA, Shepherd BE, Teeratakulpisarn N, van der Lugt J, Avihingsanon A, Ruxrungtham K, Shikuma C, Phanuphak P, Ananworanich J. Anal squamous intraepithelial lesions among HIV-positive and HIV-negative men who have sex with men in Thailand. *Sex Transm Infect.* 2009 Jun 11. [Epub ahead of print]
 17. van der Lugt J, Lange J, **Avihingsanon A**, Ananworanich J, Sealoo S, Burger D, Gorowara M, Phanuphak P, Ruxrungtham K. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals. *Antivir Ther.* 2009;14(7):1001-4
 18. Manosuthi W, Van Tieu H, Mankatitham W, Lueangniyomkul A, Ananworanich J, Avihingsanon A, Siangphoe U, Klongugkara S, Likanonsakul S, Thawornwan U, Suntisuklappon B, Sungkanuparph S; N2R Study Team. Clinical case definition and

manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. *AIDS*. 2009 Nov 27;23(18):2467-71

19. Van Tieu H, Ananworanich J, **Avihingsanon A**, Apateerapong W, Sirivichayakul S, Siangphoe U, Klongugkara S, Boonchokchai B, Hammer SM, Manosuthi W. Immunologic Markers as Predictors of Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in HIV and Tuberculosis Coinfected Persons in Thailand. *AIDS Res Hum Retroviruses*. 2009 : 25(11):1083-9.
20. Crane M, Sirivichayakul S, Chang JJ, **Avihingsanon A**, Ubolyam S, Buranapraditkun S, Thantiworasit P, Wightman F, Locarnini S, Matthews G, Dore GJ, Ruxrungtham K, Lewin SR. No increase in HBV-specific CD8+ T cells in patients with HIV-1-HBV co-infection following HBV-active HAART. *J Virol*. 2010 Jan 6.
21. **Avihingsanon A**, Lewin SR, Kerr K, Chang JJ, Piyawat K, Napissanant N, Matthews GV, Dore GJ, Bowden S, Lang J, Ruxrungtham K Efficacy of tenofovir/emtricitabine compared to emtricitabine in antiretroviral naïve HIV/HBV coinfection in Thailand *Antiviral Ther* 15(6):917-22
22. Phanuphak N, Pattanachaiwit S, Pankam T, Pima W, Avihingsanon A, Teeratakulpisarn N, Phanuphak P. [Active voluntary counseling and testing with integrated CD4 count service can enhance early HIV testing and early CD4 count measurement: experiences from the Thai Red Cross Anonymous Clinic in Bangkok, Thailand.](#) *J Acquir Immune Defic Syndr*. 2010 Dec 13.
23. Iser DM, Avihingsanon A, Wisedopas N, Thompson AJ, Boyd A, Matthews GV, Locarnini SA, Slavin J, Desmond PV, Lewin SR. [Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression.](#) *AIDS* 14;25(2):197-205

โครงการวิจัยอื่นๆที่กำลังดำเนินการ

	ผู้วิจัยหลัก	หัวข้อ	แหล่งทุน	ปีที่ได้	ปีที่เสร็จ
	พญ.อัญชลี อวิหิงสานนท์	ประสิทธิภาพและความปลอดภัยของยาทีโนโฟเวียร์ในผู้ใหญ่	สภาวิจัยแห่งชาติ	2553	2555
	พญ.อัญชลี อวิหิงสานนท์	เภสัชจลนศาสตร์ของยาดารูนาเวียร์/ ริโทนาเวียร์ (DRV/r) ขนาด 600/100มก. วันละครั้งเทียบกับ	สำนักงานคณะกรรมการอาหารและยา อุดมศึกษา	2553	2554

		ดาร์นาเวียร์/ ริโทนาเวียร์ (DRV/r) ขนาด 600/100 มก. วันละสองครั้ง ในผู้ป่วยติดเชื้อเอชไอวีที่เคยได้รับยาต้านมาก่อน			
	พญ.อัญชลี อวิหิงสานนท์	hypophosphatemia in HIV infected patients	รัชดาสมโภช	2553	2554
	พญ.อัญชลี อวิหิงสานนท์	Glomerular Filtration Rate in HIV infected patients	สถาบันวิจัยแห่งชาติสหรัฐ	2553	2554
	ศ.นพ.เกียรติ รักษ์รุ่งธรรม	A Surveillance program for the detection of hepatitis B virus (HBV) resistance to tenofovir (TDF) in HIV-HBV co-infected patients	Bayside Health, Australia	2552	2554
	ศ.นพ.เกียรติ รักษ์รุ่งธรรม	Strategy of Starting Antiretroviral Therapy (START)	สถาบันวิจัยแห่งชาติสหรัฐ	2553	2558

งานประจำในช่วงเวลาที่จะทำการวิจัยโดยประมาณ

1. อาจารย์พิเศษ หน่วยภูมิแพ้และภูมิคุ้มกันวิทยาทางคลินิก ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย
2. นักวิจัยเต็มเวลา ศูนย์ประสานความร่วมมือเนเธอร์แลนด์ ออสเตรเลีย ไทย เพื่อการวิจัยด้านโรคเอดส์ (HIVNAT) ศูนย์วิจัยโรคเอดส์ สภากาชาดไทย

ประวัติผู้ร่วมวิจัยคนที่ 1

รองศาสตราจารย์นายแพทย์พิสิฐ ตั้งกิจวานิชย์

CURRICULUM VITAE

PISIT TANGKIJVANICH, MD., FRCP (T),

Thai Board in Gastroenterology and Hepatology

Education:

M.D., Chulalongkorn University, Bangkok, Thailand	1982-1988
Board of Internal Medicine, Thailand	1991-1994
Board of Gastroenterology and Hepatology, Thailand	1994-1996

Postgraduate Posts:

General Physician, Bungkan Hospital, Nongkai Province	1988-1991
Resident, Department of Medicine, Chulalongkorn University Hospital	1991-1994
Fellow, Gastroenterology Unit, Department of Medicine, Chulalongkorn University Hospital	1994-1996
Research Fellow, Division of Digestive Disease, UCLA School of Medicine, USA.	1999-2001

Present Post

Lecturer, Department of Biochemistry Faculty of Medicine, Chulalongkorn University	1997-1999
Assistant Professor, Department of Biochemistry Faculty of Medicine, Chulalongkorn University	1999-2005
Associated Professor, Department of Biochemistry Faculty of Medicine, Chulalongkorn University	2005-present

Member of

- The Royal College of Physicians of Thailand [RCP (T)]
- The Gastroenterological Association of Thailand (GAT)

Publications

1. Poovorawan Y, Theamboonlers A, Jantaradsamee P, Kaew-in N, Hirsch P, **Tangkijvanich P**. Hepatitis TT virus infection in high-risk groups. *Infection*. 1998;26:355-8. (IF=1.831)
2. **Tangkijvanich P**, Hirsch P, Theamboonlers A, Nuchprayoon I, Poovorawan Y. Association of hepatitis viruses with hepatocellular carcinoma in Thailand. *J Gastroenterol*. 1999;34:227-33. (IF=3.117)
3. **Tangkijvanich P**, Theamboonlers A, Hirsch P, Kullavanijaya P, Suwangool P, Poovorawan Y. TT virus infection in chronic liver disease. *Hepatogastroenterology*. 1999;46:1053-8. (IF=0.681)
4. **Tangkijvanich P**, Wittayalertpanya S, Kusonsolboon T, Thong-Ngam D, Mahachai V. Caffeine clearance study in hepatocellular carcinoma. *J Med Assoc Thai*. 1999;82:297-303.
5. Vimolket T, Theamboonlers A, **Tangkijvanich P**, Poovorawan Y. Hepatitis GBV-C infection in intravenous drug users. *Southeast Asian J Trop Med Public Health*. 1998;29:491-6.
6. Mahachai V, **Tangkijvanich P**, Wannachai N, Sumpathanukul P, Kullavanijaya P. CagA and VacA: virulence factors of *Helicobacter pylori* in Thai patients with gastroduodenal diseases. *Helicobacter*. 1999;4:143-7. (IF=2.470)
7. **Tangkijvanich P**, Tresukosol D, Sampatanukul P, Sakdikul S, Voravud N, Mahachai V, Mutirangura A. Telomerase assay for differentiating between malignancy-related and nonmalignant ascites. *Clin Cancer Res*. 1999;5:2470-5. (IF=6.488)
8. Thong-Ngam D, **Tangkijvanich P**, Isarasena S, Kladchareon N, Kullavanijaya P. A risk scoring system to predict outcome of non-variceal upper gastrointestinal bleeding in Thai patients. *J Med Assoc Thai*. 1999;82:1234-40.
9. Paritpoken N, **Tangkijvanich P**, Teerasaksilp S, Wiwanitkit V, Lertmaharit S, Tosukhowong P. Fast liver alkaline phosphatase isoenzyme in diagnosis of malignant biliary obstruction. *J Med Assoc Thai*. 1999;82:1241-6.
10. **Tangkijvanich P**, Tosukhowong P, Bunyongyod P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. *Southeast Asian J Trop Med Public Health*. 1999;30:110-4.
11. Theamboonlers A, Jantaradsamee P, Kaew-In N, **Tangkijvanich P**, Hirsch P, Poovorawan Y. The predominant genotypes of hepatitis B virus in Thailand. *Ann Trop Med Parasitol*. 1999; 93:737-43. (IF=1.652)

12. Theamboonlers A, **Tangkijvanich P**, Pramoolsinsap C, Poovorawan Y. Genotypes and subtypes of hepatitis B virus in Thailand. Southeast Asian J Trop Med Public Health. 1998;29:786-91.
13. **Tangkijvanich P**, Theamboonlers A, Hirsch P, Thongngam D, Kullavanijaya P, Poovorawan Y. Hepatitis viruses and chronic liver disease. Southeast Asian J Trop Med Public Health. 1999;30:489-95.
14. Kullavanijaya P, **Tangkijvanich P**, Poovorawan Y. Current status of infection-related gastrointestinal and hepatobiliary diseases in Thailand. Southeast Asian J Trop Med Public Health. 1999;30:96-105.
15. Sampatanukul P, Leong AS, Kosolbhand P, **Tangkijvanich P**. Proliferating ductules are a diagnostic discriminator for intrahepatic cholangiocarcinoma in FNA biopsies. Diagn Cytopathol. 2000;22:359-63. (IF=1.124)
16. Theamboonlers A, **Tangkijvanich P**, Jantaradsamee P, Hirsch P, Poovorawan Y. Prevalence of core promotor and precore mutants of hepatitis B virus in Thailand by RFLP and sequencing. Southeast Asian J Trop Med Public Health. 1999;30:750-5.
17. Mahachai V, **Tangkijvanich P**, Wannachai N, Sampatanukul P, Lertpocasombat K, Kladchareon N. Serodiagnosis of *Helicobacter pylori* infection by immunoblot assay. Asian Pac J Allergy Immunol. 2000;18:63-7. (IF=0.569)
18. **Tangkijvanich P**, Vimolket T, Theamboonlers A, Kullavanijaya P, Suwangool P, Poovorawan Y. Serum interleukin-6 and interferon-gamma levels in patients with hepatitis B-associated chronic liver disease. Asian Pac J Allergy Immunol. 2000;18:109-14. (IF=0.569)
19. Pawarode A, **Tangkijvanich P**, Voravud N. Outcomes of primary hepatocellular carcinoma treatment: an 8-year experience with 368 patients in Thailand. J Gastroenterol Hepatol. 2000;15:860-4. (IF=2.275)
20. **Tangkijvanich P**, Mahachai V, Wittayalertpanya S, Ariyawongsopon V, Isarasena S. Short-term effects of branched-chain amino acids on liver function tests in cirrhotic patients. Southeast Asian J Trop Med Public Health. 2000;31:152-7.
21. **Tangkijvanich P**, Tam SP, Yee HF Jr. Wound-induced migration of rat hepatic stellate cells is modulated by endothelin-1 through rho-kinase-mediated alterations in the acto-myosin cytoskeleton. Hepatology. 2001;33:74-80. (IF=11.355)
22. **Tangkijvanich P**, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31:302-8. (IF=2.775)

23. **Tangkijvanich P**, Kasemsupatana K, Janchai A, Kullavanijaya P, Theamboonlers A, Poovorawan Y. Prevalence and clinical relevance of serum anti-p53 antibodies in patients with cholangiocarcinoma. *Asian Pac J Allergy Immunol.* 2000;18:173-6. (IF=0.569)
24. **Tangkijvanich P**, Thong-Ngam D, Kullavanijaya P, Suwangool P. Fibrolamellar hepatocellular carcinoma in a Thai man who presented with hypoglycemia: case report and review of literature. *J Med Assoc Thai.* 2000; 83:809-16.
25. **Tangkijvanich P**, Janchai A, Charuruks N, Kullavanijaya P, Theamboonlers A, Hirsch P, Poovorawan Y. Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma. *Asian Pac J Allergy Immunol.* 2000;18:237-43. (IF=0.569)
26. **Tangkijvanich P**, Theamboonlers A, Jantaradsamee P, Hirsch P, Mahachai V, Suwangool P, Poovorawan Y. Core promoter and precore mutants of hepatitis B virus: prevalence and clinical relevance in chronic hepatitis patients. *Southeast Asian J Trop Med Public Health.* 2000;31:627-35.
27. Thong-Ngam D, **Tangkijvanich P**, Mahachai V, Kullavanijaya P. Current status of gastric cancer in Thai patients. *J Med Assoc Thai.* 2001;84:475-82.
28. Thong-Ngam D, Suwangool P, Prempracha J, **Tangkijvanich P**, Vivatvekin B, Sriratanabun A. Lactose intolerance and intestinal villi morphology in Thai people. *J Med Assoc Thai.* 2001;84:1090-6.
29. Poovorawan Y, **Tangkijvanich P**, Theamboonlers A, Hirsch P. Transfusion transmissible virus TTV and its putative role in the etiology of liver disease. *Hepatogastroenterology.* 2001; 48: 256-60. (IF=0.681)
30. Poovorawan Y, Chongsrisawat V, **Tangkijvanich P**. Problems and prevention of viral hepatitis in Thailand. *J Med Assoc Thai.* 2001;84 Suppl 1:S18-25.
31. Kernochan LE, Tran BN, **Tangkijvanich P**, Melton AC, Tam SP, Yee HF Jr. Endothelin-1 stimulates human colonic myofibroblast contraction and migration. *Gut.* 2002;50:65-70. (IF=9.766)
32. Charuruks N, **Tangkijvanich P**, Voravud N, Chatsantikul R, Theamboonlers A, Poovorawan Y. Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients. *J Gastroenterol.* 2001;36:830-6. (IF=3.117)
33. **Tangkijvanich P**, Thong-ngam D, Mahachai V, Kladchareon N, Suwangool P, Kullavanijaya P. Long term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B. *Southeast Asian J Trop Med Public Health.* 2001;32:452-8.

34. **Tangkijvanich P**, Yee HF. Cirrhosis: can we reverse fibrosis? *Eur J Surg* 2002, 168 (S587) 100-12. (IF=1.327)
35. Chui T, Wu SS, Santiskulvong C, **Tangkijvanich P**, Yee HF, Rozengurt E. Vasopressin-mediated mitogenic signaling in intestinal epithelial cells. *Am J Physiol Cell Physiol*. 2002; 282: C434-50. (IF=4.230)
36. **Tangkijvanich P**, Santiskulvong C, Melton AC, Rozengurt E, Yee HF. p38 MAP kinase mediated platelet-derived growth factor-stimulated migration of human myofibroblasts. *J Cell Physiol* 2002; 191: 351-61. (IF=4.313)
37. Saab S, Tam SP, Tran BN, Melton AC, **Tangkijvanich P**, Wong HC, Yee HF. Myosin mediates contractile force generation by hepatic stellate cells in response to endothelin-1. *J Biomed Sci* 2002; 9: 607-12. (IF=2.013)
38. **Tangkijvanich P**, Melton AC, Chitapanarux T, Yee HF. LPA and PDGF distinctly regulate hepatic myofibroblast migration through focal adhesion kinase. *Exp Cell Res* 2002; 281: 140-7. (IF=3.948)
39. **Tangkijvanich P**, Melton AC, Santiskulvong C, Yee HF. Rho and p38 MAP kinase signaling pathways mediate LPA-stimulated hepatic myofibroblast migration. *J Biomed Sci* 2003, 10, 352-8. (IF=2.013)
40. Thong-ngam D, **Tangkijvanich P**, Treeprasertsuk S, Wisedopas N, Kullavanijaya P. Effectiveness of Ranitidine Bismuth Citrate based triple therapy for treating *Helicobacter pylori*. *J Med Assoc Thai* 2002; 85: 1054-9.
41. Thong-ngam D, Thumvijit L, **Tangkijvanich P**, Janchai A, Mahachai V, Wittayalertpanya S. Caffeine clearance in patients with hepatocellular carcinoma after transcatheter oily chemoembolization treatment. *J Med Assoc Thai*. 2002; 85: 1281-7.
42. **Tangkijvanich P**, Theamboonlers A, Sriponthong M, Thong-ngam D, Kullavanijaya P, Poovorawan Y. SEN virus infection in patients with chronic liver disease and hepatocellular carcinoma. *J Gastroenterol* 2003; 38: 142-8. (IF=3.117)
43. **Tangkijvanich P**, Theamboonlers A, Sriponthong M, Kullavanijaya P, Poovorawan Y. SEN virus infection and the risk of hepatocellular carcinoma: a case-control study. *Am J Gastroenterol* 2003; 98: 2500-4. (IF=6.444)
44. Chongsrisawat V, Kongtawelert P, Tongsoongnoen W, **Tangkijvanich P**, Vejchapipat P, Poovorawan Y. Serum hyaluronan as a marker reflecting the severity of cirrhosis and portal hypertension in patients with postoperative biliary atresia. *Pediatr Surg Int* 2004; 20: 773-7. (IF=0.964)

45. **Tangkijvanich P**, Suwangool P, Mahachai V. Comparison of clinical features and survival of patients with hepatitis B- and hepatitis C-associated hepatocellular carcinoma in Thailand. *J Med Assoc Thai*. 2003, 86 (Supl 2) 250-6.
46. **Tangkijvanich P**, Kongtawelert P, Pothacharoen P, Mahachai V, Suwangool P, Poovorawan Y. Serum hyaluronan: a marker of liver fibrosis in patients with chronic liver disease. *Asian Pac J Allergy Immunol* 2003, 21: 115-20. (IF=0.569)
47. Jatuporn S, Sangwatanaroj S, Saengsiri A, Rattanaprucks S, Srimahachota S, Uthayachalerm W, Kuanoon W, Panpakdee O, **Tangkijvanich P**, Tosukhowong P. Short-term Effects of an intensive lifestyle modification program on lipid peroxidation and antioxidant systems in patients with coronary artery disease. *Clin Hemorheol Microcirc* 2003; 29: 429-36. (IF=1.814)
48. Tosukhowong P, Sangwatanaroj S, Jatuporn S, Prapunwattana P, Saengsiri A, Rattanaprucks S, Srimahachota S, Udayachalerm W, **Tangkijvanich P**. The correlation between oxidative stress markers and the risk factors of coronary artery disease in Thai patients. *Clin Hemorheol Microcirc* 2003; 29: 321-9. (IF=1.814)
49. Kongtawelert P, **Tangkijvanich P**, Ong-Chai S, Poovorawan P. Role of serum total sialic acid in differentiating between cholangiocarcinoma and hepatocellular carcinoma. *World J Gastroenterol* 2003; 9: 2178-81. (IF=2.081)
50. Poovorawan P, Theamboonlers A, Jantaradsamee P, Chatchatree P, Chongsrisawat V, **Tangkijvanich P**. Clinical features and molecular characterization of hepatitis A virus outbreak in a child care center in Thailand. *J Clin Virol* 2005; 32:24-8. (IF=3.320)
51. **Tangkijvanich P**, Thong-gnam D, Theamboonlers A, Hanvivatvong O, Kullavanijaya P, Poovorawan Y. diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma. *Hepatogastroenterology* 2004; 51: 15-9. (IF=0.680)
52. **Tangkijvanich P**, Mahachai V, Suwangool P, Poovorawan Y. Gender difference in clinicopathologic features and survival of Thai patients with hepatocellular carcinoma. *World J Gastroenterol* 2004, 10: 1547-50. (IF=2.081)
53. Payungporn S, **Tangkijvanich P**, Jantaradsamee P, Theamboonlers A, Poovorawan P. Simultaneous quantification and genotyping of hepatitis B virus by real-time PCR and melting curve analysis. *J Virol Methods* 2004, 120: 131-140. (IF=2.077)
54. Honsawek S, Chongsrisawat V, Vejchapipat P, Thawornsuk N, **Tangkijvanich P**, Poovorawan Y. Serum interleukin-8 in children with biliary atresia: relationship with disease stage and biochemical parameters. *Pediatr Surg Int* 2005; 21: 73-7. (IF=0.964)

55. Chalitchagorn K, Shuangshoti S, Hourpai N, **Tangkijvanich P**, Thong-ngam D, Voravud N, Mutirangura A. Differential LINE-1 hypomethylation level in normal tissue and in association with cancer development. *Oncogene* 2004; 23: 8841-6. (IF=7.216)
56. Vejchapipat P, **Tangkijvanich P**, Theamboonlers A, Chongsrisawat V, Chittmittrapap S, Poovorawan Y. The association between serum hepatocyte growth factor and the survival in untreated hepatocellular carcinoma. *J Gastroenterol* 2004; 39:1182-8. (IF=3.117)
57. Kullavanijaya P, Thong-ngam D, Hanvivatvong O, Nunthapisut P, **Tangkijvanich P**, Suwangool P. An analysis of eight different methods for the diagnosis of *Helicobacter pylori* infection in patients with dyspepsia. *J Gastroenterol Hepatol* 2004; 19: 1392-6. (IF=2.275)
58. **Tangkijvanich P**, Mahachai V, Komolmit P, Theamboonlers A, Poovorawan Y. Hepatitis B virus genotypes and hepatocellular carcinoma in Thailand. *World J Gastroenterol* 2005; 11: 2238-43. (IF=2.081)
59. **Tangkijvanich P**, Mahachai V, Komolmit P, Theamboonlers A, Poovorawan Y. Clinical and virological differences between Hepatitis B virus genotypes B and C: A case-control study. *J Med Assoc Thai* 2004; 87 (Suppl 2): S223-7.
60. Thong-Ngam D, **Tangkijvanich P**, Sampatanukul P, Prichakas P, Mahachai V, Tosukowong P. Direct measurement of gastric H^+/K^+ -ATPase activities in patients with or without *Helicobacter pylori*-associated chronic gastritis. *World J Gastroenterol* 2005; 11: 3514-7. (IF=2.081)
61. Suwannakarn K, **Tangkijvanich P**, Theamboonlers A, Abe K, Poovorawan Y. A novel recombination of hepatitis B virus genotypes G and C isolated from a Thai patient with hepatocellular carcinoma. *J Gen Virol* 2005; 86: 3027-30. (IF=3.092)
62. Hirankarn N, Kimkong I, Kummee P, **Tangkijvanich P**, Poovorawan Y. Interleukin-1beta gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection. *World J Gastroenterol* 2006;12:776-9. (IF=2.081)
63. Thong-Ngam D, **Tangkijvanich P**, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y. Diagnostic role of serum interleukin-18 in gastric cancer patients. *World J Gastroenterol*. 2006;12: 4473-7. (IF=2.081)
64. Chiechansin T, Chutinimitkul S, Payungporn S, Theamboonlers A, **Tangkijvanich P**, Komolmit P, Poovorawan Y. Rapid detection of lamivudine-resistance hepatitis B virus mutations by PCR-based methods. *Tohoku J Exp Med* 2006; 210: 67-78. (IF=1.286)

65. **Tangkijvanich P**, Hourpai N, Rattanatanyong P, Wisedopas N, Mahachai V, Mutrangura A. Serum LINE-1 hypomethylation level as a prognostic marker for hepatocellular carcinoma. Clin Chim Acta 2007; 379(1-2): 127-33. (IF=2.960)
66. **Tangkijvanich P**, Thong-ngam D, Mahachai V, Theamboonlers A, Poovorawan Y. Serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. [World J Gastroenterol](#) 2007; 13: 4345-9. (IF=2.081)
67. Sa-nguanmoo P, **Tangkijvanich P**, Payungporn S, Chieochansin T, Thawornsuk N, Chongsrisawat V, Poovorawan Y. Dynamics of HBV DNA levels, HBV mutations and biochemical parameters during oral antiviral therapies. Asian Pac J Allergy Immunol 2007; 25: 183-8. (IF=0.569)
68. Kummee P, **Tangkijvanich P**, Poovorawan Y, Hirankarn N. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population J Viral Hepatitis 2007; 14: 841-8. (IF=3.326)
69. Hirankarn N, Manonom C, **Tangkijvanich P**, Poovorawan Y. Association of interleukin 18 gene polymorphism (-607A/A genotype) with susceptibility to chronic hepatitis B virus infection. Tissue Antigens 2007; 70: 160-3. (IF=2.076)
70. [Honsawek S](#), [Chongsrisawat V](#), [Vejchapipat P](#), [Thawornsuk N](#), **[Tangkijvanich P](#)**, [Poovorawan Y](#). Elevation of serum stem-cell factor in postoperative biliary atresia. Pediatr Int. 2007;49:888-93. (IF=0.677)
71. Suwannakarn K, **Tangkijvanich P**, Thawornsuk N, Theamboonlers A, Tharmaphornpilas P, Yoocharoen p, Chongsrisawat V, Poovorawan Y. Molecular Epidemiological Study of Hepatitis B Virus in Thailand based on the Analysis of Pre-S and S genes. Hepatol Res 2008; 38: 244-51. (IF=1.562)
72. Sa-nguanmoo P, Thongmee C, Ratanakorn P, Pattanarangsarn R, Boonyarittichaijij R, Chodapisitkul S, Theamboonlers A, **Tangkijvanich P**, Poovorawan Y. Prevalence, whole genome characterization and phylogenetic analysis of hepatitis B virus in captive orangutan and gibbon. J Med Primatol 2008; 37: 277-89. (IF=1.047)
73. **Tangkijvanich P**, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, Kongtawelert P. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 2010; 25: 129-37. (IF=2.275)

74. **Tangkijvanich P**, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Low pretreatment serum HBsAg level and viral mutations as predictors of response to peg-interferon alpha-2b therapy in chronic hepatitis B. *J Clin Virol* 2009; 46: 117-23. (IF=3.320)
75. **Tangkijvanich P**, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Comparison between quantitative HBsAg, HBeAg and HBV DNA levels for predicting virological response to peg-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B. *Hepatol Res* 2010; 40: 269-77. (IF=1.562)
76. Akkarathamrongsin S, Praianantathavorn K, Hacharoen N, Theamboonlers A, **Tangkijvanich P**, Tanaka Y, Mizokami M, Poovorawan Y. Hepatitis C genotype 6 subtypes in Thailand and their geographic distribution. *J Med Virol* 2010; 82: 257-62. (IF=2.470)
77. Akkarathamrongsin S, Praianantathavorn K, Hacharoen N, Theamboonlers A, **Tangkijvanich P**, Poovorawan Y. Seroprevalence and Genotype of Hepatitis C Virus among Immigrant Workers from Cambodia and Myanmar to Thailand. *Intervirol* 2010; 54: 10-6 (IF=1.106)
78. Sa-nguanmoo P, **Tangkijvanich P**, Thawornsuk N, Vichaiwattana P, Praianantathavorn K, Theamboonlers A, Tanaka Y, Poovorawan Y. Molecular Epidemiological Study of Hepatitis B Virus among Migrant Workers from Cambodia, Laos and Myanmar to Thailand *J Med Virol* 2010; 85: 1341-9. (IF=2.470)
79. **Tangkijvanich P**, Sa-nguanmoo P, Mahachai V, Theamboonlers A, Poovorawan Y. Sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. *Hepatol Int* 2010; 4: 577-84 (IF=1.725)
80. Chimparlee N, Oota S, Phikulsod S, **Tangkijvanich P**, Poovorawan Y. Hepatitis B and hepatitis C virus in Thai blood donors. *Southeast Asian J Trop Med Public Health*. 2011; 42: 609-15.
81. **Tangkijvanich P**, Komolmit P, Mahachai V, Poovorawan K, Akkarathamrongsin S, Poovorawan Y. Response-Guided Therapy for Patients with Hepatitis C Virus Genotype 6 Infection: A Pilot Study. *J Viral Hepatitis* 2011 (in press).
-

ประวัติคณะผู้วิจัยคนที่ 2 และหัวหน้าโครงการวิจัยที่ 2

ผู้ช่วยศาสตราจารย์นายแพทย์วิรัช เหมอนันต์ธวัช

1. ชื่อ - นามสกุล (ภาษาไทย) ผู้ช่วยศาสตราจารย์นายแพทย์วิรัช เหมอนันต์ธวัช

ชื่อ - นามสกุล (ภาษาอังกฤษ) Wirach Maek-a-Nantawat

2. หมายเลข บัตรประจำตัวประชาชน 3100904200420

3. ตำแหน่งปัจจุบัน แพทย์วิจัย

4. หน่วยงาน สาขาวิชาโรคภูมิแพ้และภูมิคุ้มกันวิทยาคลินิก ภาควิชาอายุศาสตร์

คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

สถานที่ติดต่อ ศูนย์ประสานความร่วมมือระหว่าง ไทย ออสเตรเลีย เนเธอร์แลนด์

เพื่อการศึกษาวิจัยทางคลินิกด้านโรคเอดส์ (HIV-NAT),

ศูนย์วิจัยโรคเอดส์ สภากาชาดไทย 104 ถนนราชดำริ ปทุมวัน กรุงเทพมหานคร 10330

หมายเลขโทรศัพท์ 081-830-7467, 02-652-3040 และ 02-256-4152 โทรสาร 02-252-5779

E-mail wirach.m@hivnat.org

5. ประวัติการศึกษา

มหาวิทยาลัย	ปริญญา	สาขาวิชา	ปีที่ได้รับ พ.ศ.
มหาวิทยาลัยมหิดล	พ.บ. (เกียรตินิยมอันดับ1)	แพทยศาสตร์ (คณะแพทยศาสตร์รพ.รามาธิบดี)	2537
มหาวิทยาลัยสงขลานครินทร์	ประกาศนียบัตร	STD&HIV/AIDS	2538
มหาวิทยาลัยมหิดล	ประกาศนียบัตรชั้นสูง	อายุรศาสตร์เขตร้อนและสุขวิทยา	2539
มหาวิทยาลัยมหิดล	ประกาศนียบัตรชั้นสูง	วิทยาศาสตร์การแพทย์	2540
มหาวิทยาลัยมหิดล และ แพทยสภา	วุฒิบัตรแสดงความรู้ความ ชำนาญ	อายุรศาสตร์ทั่วไป	2543
จุฬาลงกรณ์มหาวิทยาลัย	วท.ม.	อายุรศาสตร์	2548
สมาคมโรคภูมิแพ้และอิมมู- โนวิทยาและราชวิทยาลัยอา- ยุรแพทย์แห่งประเทศไทย	วุฒิบัตรแสดงความรู้ความ ชำนาญ	อายุรศาสตร์โรคภูมิแพ้และอิมมูโน วิทยาคลินิก	2548

6. สาขาวิชาการที่มีความชำนาญพิเศษ (แตกต่างจากวุฒิการศึกษา) ระบุสาขาวิชาการ

โรคภูมิแพ้และภูมิคุ้มกันโรคติดเชื้อ

โรคเอดส์และโรคที่สัมพันธ์กับเอดส์ โรคทางเพศสัมพันธ์

โรคติดเชื้อในเขตร้อน

7. ประสบการณ์ที่เกี่ยวข้องกับการบริหารงานวิจัยทั้งภายในและภายนอกประเทศ

Publication

1. **Maek-a-nantawat W**, Chantaphakul H, Ruxrungtham K. Immune reconstitution syndrome presenting as diffused angioedema. *J Allergy Clin Immunol* 2005;115(Suppl 1):S19.
2. **Maek-a-nantawat W**, Buranapraditkun S, Ruxrungtham K. Intracellular IL-17 expression in peripheral blood CD4+ and CD4- T cells of HIV-infected individuals. *J Allergy Clin Immunol* 2006;117(Suppl 1):S287.
3. Tansuphaswadikul S, **Maek-a-nantawat W**, Phonrat B., et al. Comparison of one week with two week regimens of amphotericin B both followed by fluconazole in the treatment of cryptococcal meningitis among AIDS patients. *J Med Assoc Thai* 2006;89:1677-85.
4. **Maek-a-nantawat W**, Chantaphakul H, Ruxrungtham K. Skin reaction after desensitization not predict the outcome of short course sulfa desensitization protocol among AIDS patients. *J Allergy Clin Immunol* 2007;119(Suppl 1):S323.
5. **Maek-a-nantawat W**, Buranapraditkun S, Klaewsongkram J, Ruxrungtham K. Increased IL-17 production both in T-helper (Th17) and CD4-negative T-cells in HIV infection. *Viral Immunol* 2007; 20:66-75.
6. Tansuphasawadikul S, Aung SE, Phonrat B, Kaewkungwal J, Pitisuttithum P, **Maek-a-nantawat W**. Predisposing factors of nevirapine associated toxicity among AIDS patients with low baseline CD4 count. *Asian Pacific J Allergy Immunol* 2007;25:147-54.
7. **Maek-a-nantawat W**. The Immunocompromised traveler. *J Trop Med Parasitol* 2007;30:26--42.
8. **Maek-a-nantawat W**, Maythaarttaphong S, Suphan R, Chueathai H, Phantong U, Khaminthakul D, Boontanom K, Sarapat S, Tomkum S, Silachamroon U. Knowledge and concerns of treatment and care among Thai allergy patients in Rayong Province, Thailand. *World Allergy Organization* 2007;Nov:S207-S208.
9. **Maek-a-nantawat W**, Maythaarttaphong S, Suphan R, Chueathai H, Phantong U, Khaminthakul D, Boontanom K, Sarapat S, Tomkum S, Silachamroon U. Atopy history in family associated with persistent allergic symptoms in Thai population. *World Allergy Organization* 2007;Nov:S209.
10. **Maek-a-nantawat W**, Silachamroon U. Asthma control and patient satisfaction after treatment of omalizumab among moderate to severe asthma: 1 year observation. *J Allergy Clin Immunol* 2009;123(Suppl 2):S158.
11. **Maek-a-nantawat W**, Phonrat B, Dhitavat J, Naksrisook S, Muanaum R, Ngamdee V, Pitisuttithum P. Safety and Efficacy of CKBM-A01, a Chinese Herbal Medicine, Among Asymptomatic HIV Patients. *Southeast Asian J Trop Med Public Health* 2009;40(3):494-501.

12. Areechokchai D, Bowonwatanuwong C, Phonrat B, Pitisuttithum P and **Maek-a-nantawat W**. Pregnancy outcomes among HIV-infected patients on antiretroviral treatment. *Open AIDS* 2009;3:8-13.
13. **Maek-a-nantawat W**, Silachamroon U. Presence of autoimmune antibody in chikungunya infection. *Case Report Med* 2009;840183, doi:10.1155/2009/840183.
14. Aramaki M, Silachamroon U, Desakorn V, **Maek-a-nantawat W**, Waiwaruwut J, Jutiwarakun K, Kim JH, Pitisuttithum P. Immune reconstitution inflammatory syndrome in adult human immunodeficiency virus-infected patients in Thailand. *Southeast Asian J Trop Med Public Health* 2010;41(1):138-145.
15. Jayathunge MPH, Pitisuttithum P, Bowanwatanuwong C, **Maek-a-nantawat W**, Phonrat B, Pitisuttithum P. Psychosocial burden of abnormal Pap smears among HIV-infected women at Chonburi Hospital, Thailand. *Southeast Asian J Trop Med Public Health* 2010;41(1):224-234.
16. **Maek-a-nantawat W**, Huntrup A, Malakul K, Silachamroon U. Atopic diseases share the cake of association with chronic urticaria. *J Allergy Clin Immunol* 2010;(Suppl 2):S112.
17. Soe AN, Tansuphaswadikul S, Phonrat B, Boonpok L, Tepsupa S, Japrasert C, **Maek-a-nantawat W**. Early viral suppression predicting long-term treatment success among HIV patients commencing NNRTI-based antiretroviral therapy. *J Antivir Antiretrovir* 2010;2;040-044.
18. Lertnawapan R, **Maek-a-nantawat W**. Anaphylaxis and biphasic phase in Thailand: 4-year Observational Study. *Allergol Intern* 2010 (in press).

HIV Research

1. Phase I/II trial of Pasteur Merieux Connaught (PMC) Live Recombinant ALVAC-HIV (vCP 1521) Priming with VaxGen gp 120 B/E (AIDSVAXTM B/E) Boost in Thai HIV-Seronegative Adults.
Secondary investigator, Apr 2000-Aug 2002
2. Observational Probe Study of in Vitro Immune Response Parameters the Candidate HIV-1 Vaccine Antigens among Subject from Thailand
Secondary investigator, Feb 2001-May 2002
3. Safety and Therapeutic Effects of Jin Huang Chinese Medicine in Uncomplicated HIV-1 Patients
Secondary investigator, May 2001-Jun 2003
4. A Two-stage, phase II study to evaluate the safety and efficacy of CKBM-A01 in treating HIV patients in Thailand.
Co-investigator, March 2006- June 2008
5. A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp 120 B/E (AIDSVAX[®] B/E) Boosting in HIV-uninfected Thai Adults.
M.D. supervisor, Oct 2003-Nov 2009
6. A Worldwide, Phase I, Dose-Escalating Study of the Safety, Tolerability, and Immunogenicity of a 3- Dose Regimen of the MRKAd5 HIV-1 gag Vaccine in Healthy Adults.
Secondary Investigator, June 2005- Oct 2008
7. Early access of MK-0518 in combination with an optimized background antiretroviral therapy (OBT) in highly treatment experienced HIV-1 infected patients with limited to no treatment options
Principle Investigator, January 2007- August 2010
8. A phase 2b/3, randomised, double blind, dose confirming study of the safety, efficacy and tolerability of apricitabine versus lamivudine in treatment-experienced HIV-1 infected patients with the M184V mutation in reverse transcriptase
Co-investigator, January 2008- March 2010
9. Travel information among HIV infected individuals: association with medical and psychosocial concerns.
Principle Investigator, July 2008- April 2010

Non-HIV Research

1. Immunogenicity and Safety of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women With an Immunogenicity Bridge Between the HPV 16 Component of the Quadrivalent Vaccine and the Monovalent HPV 16 Vaccine Pilot Manufacturing Material---The FUTURE I Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease). Protocol No. 012-01/013-01
Secondary Investigator, Jan 2002- June 2003
2. Comparison of the Efficacy and Safety of One Inhalation of Symbicort® Turbuhaler® 160/4.5 µg b.i.d. plus as-needed with Two Inhalation of Seretide™ Evohaler™ 25/125 b.i.d. plus Terbutaline Turbuhaler® 0.4 mg as-needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg b.i.d. plus Terbutaline Turbuhaler® 0.4 mg as-needed. A 6-month, randomized, double-blind, double dummy, parallel-group, active-controlled, multicentre, phase III B study in adult and adolescent asthmatic patients.
Sub-Investigator, Nov 2003- Jun 2005
3. A 24-week, Double-blind, Parallel Group, Placebo and Active Controlled Study to Investigate the Efficacy and Safety of Daily Oral Roflumilast Taken with Low Dose Inhaled Corticosteroids in Patients with Chronic Asthma.
Sub-Investigator, May 2003- May 2005
4. Bioequivalence Study of Generic Didanosine Tablets to Innovator Didanosine 200 mg in Healthy Thai Volunteers.
Clinical Investigator, August 2006-June 2007
5. In Vivo Bioequivalence Study of 5 mg Levocetirizine Tablets Preparations in Healthy Thai Male Volunteers
Principle Investigator, July 2007-January 2008
6. Gnathostomiasis and correlation of skin test with *Gnathostoma spinigerum* fractionated antigen and IgE.
Principle Investigator, June 2006- September 2010
7. Establishment of a *Shigella sonnei* Challenge Model for evaluation of future vaccine candidates.
Clinical Investigator, January 2007- March 2008

8. Phase I/II safety and immunogenicity of pandemic live attenuated influenza vaccine (PLAIV) candidate strain A/17/CA/2009/38 (H1N1) in healthy adults

Coinvestigator, July 2009- Jan 2010

ประวัติผู้ร่วมวิจัยคนที่ 3

รองศาสตราจารย์แพทย์หญิงจินตนาถ อนันต์วรณิชย์

(ภาษาไทย) แพทย์หญิงจินตนาถ อนันต์วรณิชย์

ตำแหน่งทางวิชาการ อาจารย์พิเศษ

(ภาษาอังกฤษ) Jintanat Ananworanich, M.D, Ph.D

ภาควิชา สาขาวิชาโรคภูมิแพ้และภูมิคุ้มกัน ภาควิชาอายุศาสตร์ คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

โทรศัพท์ 02-652-3040

โทรสาร 02-252-5779

E-mail Jintanat.a@hivnat.org

ที่อยู่ปัจจุบัน ศูนย์วิจัยโรคเอดส์ สภากาชาดไทย 104 ถนนราชดำริ ปทุมวัน กรุงเทพมหานคร 10330

โทรศัพท์ 02-254 2566, 081-341-4644

ประวัติการศึกษา

มหาวิทยาลัย	ปริญญา	สาขาวิชา	ปีที่ได้รับ พ.ศ.
มหาวิทยาลัยสงขลานครินทร์	ปริญญาตรี ด้านการแพทย์	แพทยศาสตรบัณฑิต	2535
มหาวิทยาลัยสงขลานครินทร์	แพทย์ประจำบ้าน	กุมารแพทย์	2536
National Institute of Allergy and Infectious Diseases/Laboratory of Dr. Anthony S. Fauci, Maryland, USA	อาสาสมัครงานวิจัย	วิจัยด้านโรคเอดส์	2537
University of Chicago, USA	แพทย์ใช้ทุน	กุมารแพทย์	2538
University of Chicago, USA	แพทย์ประจำบ้าน	กุมารแพทย์	2540
Baylor College of Medicine/Texas Children's Hospital, Houston, USA	แพทย์ประจำบ้านต่อยอดด้าน ภูมิแพ้และภูมิคุ้มกัน	ภูมิแพ้และภูมิคุ้มกัน	2542
Baylor College of Medicine/Texas Children's Hospital, Houston, USA	แพทย์ประจำบ้านต่อยอดด้าน คลินิกและห้องปฏิบัติการด้าน ภูมิคุ้มกัน	คลินิกและ ห้องปฏิบัติการ ด้านภูมิคุ้มกัน	2543
University of Amsterdam, Amsterdam, Netherlands	ปริญญาเอก	แพทยศาสตร์	2551

Manuscripts

1. Pumpradit W, **Ananworanich J**, Lolak S, Shikuma C, Paul R, Siangphoe U, Chaoniti N, Kaew-on P, Paris R, Ruxrungtham K, Valcour V and the Southeast Asia Research Collaboration with Hawaii (SEARCH) 005 protocol team. Neurocognitive Impairment and Psychiatric Comorbidity in Well-controlled HIV-infected Thais from the 2NN Cohort Study. J Neurovirology. In Press
2. Van Tieu H, Phanuphak N, **Ananworanich J**, Vatanparast R, Jadwattanakul T, Pharachetsakul N, Mingkwanrungrueng P, Teeratakulpisarn S, Teeratakulpisarn N, Methajittiphun P, Hammer S, Chiasson MA, Phanuphak P, Acceptability of Male Circumcision for the Prevention of HIV among High-risk Heterosexual Men in Thailand. Sexually Transmitted Disease. In Press
3. Gibb DM, Green H, Compagnucci A, Klein N, Lallemand M, Lyall H, Nadal D, **Ananworanich J**, Babiker A, Bunupuradah T, Darbyshire J, De Rossi A. Response to Planned Treatment Interruptions in HIV-infection varies across Childhood in the PENTA 11 Trial. AIDS. In Press
4. Arroyo MA, Phanuphak N, Krasaesub S, Sirivichayakul S, Assawadarachai V, Poltavee K, Tippawan Pankam T, **Ananworanich J**, Paris R, Tovanabutra S, Kijak G, McCutchan FE, Phanuphak P, Kim JH, de Souza M. Increased Prevalence of Non-CRF01_AE HIV-1 Strains among High-Risk Clients Attending the Thai Red Cross Anonymous Clinic in Bangkok, Thailand. AIDS Research and Human Retroviruses. In Press
5. Van Tieu H, **Ananworanich J**, Avihingsanon A, Apateerapong W, Sirivichayakul S, Klongutkara S, Boonchokchai B, Siangphoe U, Hammer S, Manosuthi W. Immunologic Markers as Predictors of Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome in HIV and TB Co-infected Persons in Thailand. AIDS Research and Human Retroviruses. 2009 Nov 3.
6. Manosuthi W, Van Tieu H, Tantanathip P, Mankatitham W, Lueangniyomkul A, **Ananworanich J**, Avihingsanon A, Siangphoe U, Klongutkara S, Thawornwan U, Suntisuklappan B, Sungkanuparph S, for the N2R Study Team. Clinical Case Definition and Manifestations of Paradoxical Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome. AIDS 2009 23(18):2467-71.
7. Nüesch R, Gayet-Ageron A, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Chautrakarn S, Ruxrungtham K, Hirschel B, **Ananworanich J**. and the STACCATO study group. The Impact of Combination Antiretroviral Therapy and its Interruption on Anxiety, Stress, Depression and Quality of Life in Thai Patients. Open AIDS Journal 2009;3:38-45
8. Puthanakit T, van der Lugt J, Bunupuradah T, **Ananworanich J**, Gorowara M, Phasomsap C, Jupimai T, Boonrak P, Pancharoen C, Burger D, Ruxrungtham K.

Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. *J Antimicrobial Therapy* 2009; 64(5):1080-6.

9. Li AH, Phanuphak N, Sahasrabuddhe VV, Chaithongwongwatthana S, Vermund SH, Jenkins CA, Shepherd BE, Teeratakulpisarn N, van der Lugt J, Avihingsanon A, Ruxrungtham K, Shikuma C, Phanuphak P, **Ananworanich J**. Anal squamous intraepithelial lesions among HIV-positive and HIV-negative men who have sex with men in Thailand. *Sexually Transmitted Infections*. 2009; June 11
10. Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P, Puthanakit T, Kerr SJ, Ruxrungtham K, Chotpitayasunondh T, Hirschel B, **Ananworanich J** and HIV-NAT 013 study team. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors. *International Journal of Infectious Diseases*. 2009; Aug 20
11. Calmy A, Nguyen A, Montecucco F, Gayet-Ageron A, Burger F, Mach F, Carr A, Ubolyam S, Hirschel B and **Ananworanich J** for STACCATO study team. HIV activates markers of cardiovascular risk in a randomized scheduled-treatment interruption trial (STACCATO). *AIDS*. 2009; 23(8):929-39
12. van der Lugt J, Gorowara M, Avihingsanon A, Burger D, **Ananworanich J**, Sringam K, Kerr S, Wit F, Lange J, Ruxrungtham K. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals. *AIDS* 2009;23(9):1176-9
13. Puthanakit T, Kerr SJ, **Ananworanich J**, Bunupuradah T, Boonrak P, Butterworth O, Srisanthana V. Immunological Recovery in Children starting NNRTI-based HAART in a resource limited setting. *Pediatric Infectious Diseases Journal*. 2009;28(6):488-92
14. Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, Mengthaisong T, Mahanontharit A, Lumbiganon P, Burger D, Ruxrungtham K, **Ananworanich J**, and HIV-NAT 017 Study Team. Safety and Efficacy of Double Boosted Protease inhibitors, Saquinavir and Lopinavir/ritonavir, in Pre-treated Children at 96 Weeks. *Antiviral Therapy* 2009;14(2):241-248
15. Valcour VG, Shiramizu B, Sithinamsuwan P, Nidhinandana S, Ratto-Kim S, **Ananworanich J**, Siangphoe U, Kim JH, de Souza M, Degruittola V, Paul RH, Shikuma CM for the SEARCH 001 protocol team. HIV DNA and Cognition in a Thai Longitudinal HAART Initiation Cohort: The SEARCH 001 Cohort Study. *Neurology*. 2009;72(11):992-8.
16. Bunupuradah T, Puthanakit T, Pancharoen C, Butterworth O, Phanuphak P, **Ananworanich J**. Henoch-Schönlein purpura and thrombocytopenia after planned antiretroviral treatment interruption in a Thai girl with HIV infection. *Int J Infect Dis*. 2009 Jan;13(1):e31-3.
17. Langford S, Gayet-Ageron G, Duncombe C, Jupimai T, Mahanontharit A, Kiartiburanakul S, Munsakul W, Ruxrungtham K, Hirschel B, **Ananworanich J** and the Staccato Study Group. Supersensitive Viral Load Assay in Predicting CD4-guided Treatment Failure. *The Open Virology Journal*, 2008, 2, 69-73

18. **Ananworanich J**, Kosalaraksa P, Engchanil C, Pancharoen C, Lumpiganon P, Intasan J, Apateerapong W, Chuenyam T, Ubolyam S, Bunupuradah T, Phanuphak P and the HIV-NAT 010 Study Team. A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection. *AIDS Research and Therapy*. 2008 Oct 28;5(1):24
19. **Ananworanich J**, Phanuphak N, de Souza M, Paris R, Arroyo MA, Trichavaroj R, Sirivichayakul S, Shikuma C, Phanuphak P, Kim J. Incidence and Characterization of Acute HIV-1 Infection in a High-Risk Thai Population. *J Acquir Immune Defic Syndr*. 2008 Oct 1;49(2):151-5
20. **Ananworanich J**, Puthanakit T, Saphonn V, Cooper DA, Ruxrungtham K. Lessons from a multicenter pediatric HIV trial. *Lancet*. 2008; 372: 356-7
21. Mangclaviraj S, Kerr SJ, Chaithongwongwatthana S, **Ananworanich J**, Hirschel B, Emery S, Cooper DA, Chotnopparatpattara P, Ruxrungtham K, Phanuphak P. Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting. *Int J STD AIDS* 2008;19:529-532
22. Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Ubolyam S, Pancharoen C, Lumbiganond P, Burger D, Ruxrungtham K, Schutz M, **Ananworanich J**, and the HIV-NAT 017 Study Team. Double boosted protease inhibitors, saquinavir and lopinavir/ritonavir, in nucleoside pre-treated children at 48 weeks. *Pediatrics Infectious Diseases J*. 2008: Jul;27(7):623-8
23. **Ananworanich J**, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul D, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B and the Staccato Study Group. Long term efficacy efficacy and safety of first line therapy with once daily saquinavir/ritonavir. *Antiviral Therapy*. 2008: 13:375-380
24. **Ananworanich J**, Pumpradit W, Apateerapong W, Siangphoe U, Saenawat S, Phanuphak P, Hirschel B. Preference for CD4-guided versus continuous HART in Thailand. *AIDS Care*. 2008;20(3):327-30
25. **Ananworanich J**, Nuesch R, Cote HCF, Kerr SJ, Hill A, Jupimai T, Laopraynak N, Saenawat S, Ruxrungtham K and Hirschel B. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine—a Staccato trial substudy. *Journal Antimicrobial Chemotherapy*. March 12, 2008 (Epub)
26. Nuesch R, **Ananworanich J**, Srasuebkul P, Chetchotisakd P, Prasithsirikul W, Klinbuayam W, Mahanontharit A, Jupimai T, Ruxrungtham K, Hirschel B on behalf of the Staccato Hepatitis B Study Group. Interruptions of Tenofovir/Emtricitabine Based ART in Patients with HIV/HBV Co-Infection. *AIDS*. 2008;22(1):152-4
27. **Ananworanich J**, Jupimai T, Siangphoe U, Mekmullica J, Sosothikul D, Pancharoen C. Behavioral and emotional problems in Thai children with HIV compared to children with and without chronic diseases. *Journal of the International Association of Physicians in AIDS Care*. 2008;7(1):52-3

28. Vemula S, Kerr S, Pancharoen C, Siripong A, Kosalaraksa P, Engchanil C, Chuamchaitrakool A, Intasan J, Lumbiganond P, Phanuphak P, **Ananworanich J**. Incidence and Risk Factors for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)-Related Rash in Thai Children with HIV Infection. *J Med Assoc Thailand*. 2007; 90 (11):2537-41
29. Boom JH, Kösters E, Duncombe C, Kerr SJ, Hirschel B, Ruxrungtham K, de Mast Q, Kosalaraksa P, Ulbolyam S, Jupimai T, **Ananworanich J** and The Staccato Study Group. Ferritin during structured treatment interruption of HAART. *HIV Medicine*. 2007; 8(6):388-395
30. Safreed-Harmon S, Siripong A, Kerr SJ, Gruskin S, Pancharoen P, **Ananworanich J**. Antiretroviral therapy adherence did not differ between Thai children with biological versus non-biological parents. *Clinical Infectious Diseases*. 2007; 45(5):669-70.
31. Leng LM, Pancharoen C, Bunupuradah T, Thisyakorn U, Trinavarat P, Sosothikul D, **Ananworanich J**. Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in a child with advanced human immunodeficiency virus (HIV) disease. *J Med Assoc Thailand*. 2007;90 (9):1937-42.
32. Gayet-Ageron, A, **Ananworanich J**, Jupimai T, Chetchotisakd P, Prasithsirikul W, Ubolyam S, Le Braz M, Ruxrungtham K, Rooney J, Hirschel B. No change in calculated creatinine clearance after tenofovir initiation among Thai patients. *J Antimicrobial Chemotherapy*. 2007;59(5):1034-7
33. Kerr SJ, Duncombe C, Avihingsanon A, **Ananworanich J**, Boyd MA, Sopa B, Chuenyam T, Cooper DA, Lange JM, Phanuphak P, Ruxrungtham K. Dyslipidemia in an Asian Population Following Treatment for Two Years with Protease Inhibitor Containing Regimens. *Journal of the International Association of Physicians in AIDS Care* 2007; 6(1):36-46
34. **Ananworanich J**, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genne U, Nuesch R, Vernazza P, Bernasconi E, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B, the Staccato Study, the Swiss HIV Cohort Study. CD4-guided schedule treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the Staccato Randomized Trial. *The Lancet* 2006;368:459-65
35. Bunupuradah T, Wannachai S, Chuamchaitrakool A, Intasan J, Nuchapong T, Neiss W, Kramm K, Pancharoen C, Burger D, **Ananworanich J**. Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals. *AIDS Res Ther* 2006;3:30
36. **Ananworanich J**, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Schutz M, Snowden W, Ruxrungtham K and the Staccato Study Team. Absence of resistance mutations in antiretroviral-naïve patients treated with ritonavir-boosted saquinavir. *Antiviral Therapy* 2006;11(5):631-5

37. Nuesch R, Srasuebkul P, **Ananworanich J**, Ruxrungtham K, Phanuphak P, Duncombe C. Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. *J Antimicrobial Chemotherapy* 2006;58(3):637-44
38. Koekkoek S, Eggermont L, De Sonnevile L, Jupimai T, Wicharuk S, Apateerapong W, Chuenyam T, Lange J, Wit F, Pancharoen C, Phanuphak P, **Ananworanich J**. Effects of highly active antiretroviral therapy (HAART) on psychomotor performance in children with HIV disease. *J Neurology*, 2006;253(12):1615-24
39. **Ananworanich J**, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, Pancharoen C, Engchanil C, Ruxrungtham K, Burger D and the HIV-NAT 017 Study Team. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside pre-treated children. *Pediatrics Infectious Diseases J*. 2005;24:874-9
40. **Ananworanich J**, Hill A, Siangphoe U, Hirschel B for The Staccato Study Group A prospective study of efficacy and safety of once daily saquinavir/ritonavir plus 2 NRTIs in treatment naïve Thai patients. *Antiviral Therapy*. 2005;10:761-7
41. Autar R.S, Boffito M, Hassink E, Wit F., **Ananworanich J.**, Siangphoe U, Pozniak A, Cooper D, Phanuphak P, Lange J, Ruxrungtham K, and Burger D The interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and United Kingdom patients. *Journal of Antimicrobial Chemotherapy*. 2005: 56(5):908-13
42. **Ananworanich J**, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mananontharit A, Ubolyam U, Cooper D, Phanuphak P, Ruxrungtham K. HAART re-treatment in patients on CD4-guided therapy achieved similar virological suppression compared to patients on continuous HAART: HIV-NAT 001.4 study. *J Acquir Immune Defic Syndr*. 2005: 39 (5):523-9.
43. **Ananworanich J**, Chantapakul H, Teeratakulpisarn S, Siangphoe U, Ubolyam S, Chuenyam T, Ungsedhaphan C, Lange J, Cooper D, Phanuphak P, Ruxrungtham K. No effect of interleukin-2 on IgE levels given in addition to antiretroviral therapy in HIV-infected adults with CD4 > 300 cells/mm³. *Asian Pacific J Allergy Immunol*. 2005: 23(1):23-8
44. Nuesch R, **Ananworanich J**, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K. Development of resistance after CD4 guided structured treatment interruptions in HIV infected patients treated with highly active antiretroviral therapy after dual nucleoside treatment. *Clinical Infectious Diseases*. 2005;40 (5): 728-34
45. Cardiello PG, Hassink E, **Ananworanich J**, Srasuebkul P, Samor T, Mahanontharit A, Ruxrungtham K, Hirschel B, Lange J, Phanuphak P, Cooper DA. Prospective randomized trial of structured treatment interruption (STI) in patients with chronic HIV infection. *Clinical Infectious Diseases*. 2005;40(4):594-600
46. Fagard C, Bandelier CY, **Ananworanich J**, Günthard H, Perneger T, García F, Hirschel B for the SSITT and Staccato study groups. Biphasic decline of CD4 cell count during scheduled treatment interruptions (STIs). *AIDS*. 2005;19(4):439-41

47. **Ananworanich J**, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, Phanuphak P, Ruxrungtham K, Lange J, Cooper DA. Incidence, characteristics and risk factors for NNRTI-associated rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. *AIDS*. 2005;19:185-192
48. Lolekha R, Sirivichayakul S, Saengphoe U, Pancharoen C, Kaewchana S, Apateerapong W, Ubolyam S, Chotpitayasunondh T, Ruxrungtham K, Phanuphak P, **Ananworanich J**. Dual NRTI resistance in children with HIV clade A/E. *Clinical Infectious Diseases*. 2005;40(2):309-12
49. **Ananworanich J**, Siangphoe U, Mahanontharit A, Hill A, Hirschel B, Ruxrungtham K. Saquinavir Cmin before and after Switching NRTI to Tenofovir in Patients Treated with Once-daily Saquinavir-hard gel capsule/ritonavir 1600 mg/100 mg. *Antiviral Therapy*. 2004;9:1035-6.
50. **Ananworanich J**, Pancharoen C, Sirivichayakul S, Buranapraditkun S, Apateerapong W, Ubolyam S, Ruxrungtham K. Undetectable plasma HIV-1 RNA with strong gag-pol specific interferon-g ELISPOT response in an HIV-1 clade A/E-infected child untreated with antiretroviral therapy. *Asian Pac J Allerg Immunol*. 2004 22:165-69
51. Autar RS, **Ananworanich J**, Apateerapong W, Sankote J, Hill A, Hirschel B, Cooper D, Lange J, Phanuphak P, Ruxrungtham K, Burger D. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. *J Antimicrob Chemother*. 2004 Oct;54(4):785-90
52. **Ananworanich J**, Chuenyam T, Teeratakulpisarn S, Boyd MA, Ruxrungtham K, Lange J, Cooper D, Phanuphak P. Creation of a drug fund for post-clinical trial access to antiretrovirals. *The Lancet*. 2004; 364:101-2
53. **Ananworanich J**. Antiretroviral therapy-related Hyperlactatemia. *Pediatrics Infectious Diseases J*. 2004 Apr;23(4):375
54. Apateerapong W, **Ananworanich J**. Participation in randomized trials in developing countries. *J. Pediatrics*. 2004; 144 (1):140
55. **Ananworanich J**, Nuesch R, Le Braz M, Chetchotisakd P, Khanna N, Ebnöther C, Vibhagool A, Wicharuk S, Ubolyam S, Ruxrungtham K, Furrer H, Cavassini M, Bernasconi E, Vernazza P, Genné D, Yerly S, Cooper D, Phanuphak P, Hirschel B, and the Swiss HIV Cohort Study. Failures of one week on, one week off anti-retroviral therapies. *AIDS* 2003;17:F33-37
56. **Ananworanich J**, Phanuphak N, Nuesch R, Apateerapong W, Ubolyam S, Phanuphak P, Ruxrungtham K. Recurring thrombocytopenia associated with structured treatment interruption in HIV infection. *Clinical Infectious Diseases*. 2003; 37 (5):723-5
57. **Ananworanich J**, Nuesch R, Teeratakulpisarn S, Srasuebkul P, Chuenyam T, Siangphoe U, Ungsedhaphand C, Phanuphak P, Ruxrungtham K. In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor versus non-protease inhibitor-based highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 2003; 32(5):570-2
58. **Ananworanich J**, Tulloch O, Morsbach K. AIDS Orphan (correspondence). *New Engl J Med* 2002; 347(18):1455-6.

59. Gozum EG, **Ananworanich J**, Hanson IC, Shearer WT. Herbal tea formula practice, nutritional insufficiency and impairment of cell-mediated immunity in an infant with *Pseudomonas aeruginosa* sepsis. *Allergy and Clinical Immunology International*. 2000;12:178-80.
60. **Ananworanich J**, Garrido D, Chintagumpala M, Hanson IC. Successful desensitization in a child with carboplatin allergy: *Pediatric Asthma, Allergy & Immunology* 1998; 12(4):273-6.
61. Weissman D, Li Y, **Ananworanich J**, Fauci AS, et al. Three populations of cells with dendritic morphology exist in the peripheral blood, only one of which is infectable with human immunodeficiency virus type 1. *Proc Natl Acad Sci* 1995; 92:826-30.

Review Articles and Chapters

1. Sohn AH and **Ananworanich J**. Highly active antiretroviral therapy for children with treatment failure. *HIV Therapy*. In Press
2. Duncombe C, Avihingsanon A, Hemachandra A, van der Lugt J, **Ananworanich J**, Ohata J, Puthanakit T, Bunupuradah T, Ruxrungtham K. The 12th Bangkok International Symposium on HIV Medicine. *HIV Therapy* 2009; 3(3): 225-8
3. Duncombe C, **Ananworanich J**, Phanuphak N, Vermund SH. Evidence-based Strategies for Preventing HIV Transmission and the Thailand Perspective. *Asian Biomedicine* 2009;3(1):39-52
4. Bunupuradah T, Aupibul L, **Ananworanich J**, Puthanakit T. The effectiveness of highly active antiretroviral therapy among HIV-infected children in Asian countries. *Asian Biomedicine* 2009;3(1):89-100
5. Alter G, **Ananworanich J**, Pantophlet R, Rybicki EP, Buonaguro L. Report on the AIDS Vaccine 2008 Conference. *Human Vaccine*. 2009 Mar 8;5(3).
6. Phanuphak P, Chasombat S, **Ananworanich J**. HAART in Medium Human Development Countries: Case Study of Thailand. In *A Decade of HAART: Historical Perspectives and Future Directions*. John G Bartlett, Joep M A Lange, Alan Whiteside, Jose M Zuniga- Editors, 2008
7. Sohn A, **Ananworanich J**. How can we simplify ART therapy in children? *Current Opinion in HIV/AIDS*. 2007;2:426-30
8. **Ananworanich J**. Reaching undetectable viral loads after initial HIV treatment. *Future HIV Therapy* 2007; 1(1): 81-89
9. Langford S, **Ananworanich J**, Cooper DA. Predictors of Disease Progression in HIV infection: A Review. *AIDS Research and Therapy*. *AIDS Research and Therapy* 2007; 4:11
10. **Ananworanich J**, Hirschel B. Intermittent therapy for the treatment of chronic HIV infection. *AIDS*. 2007 Jan 11;21(2):123-134
11. Pancharoen C, **Ananworanich J**, Thisyakorn U. Preventive Strategies of Perinatal HIV-1 Transmission: An Experience from Thailand. *Sociedad Iberoamericana de Información Científica (SIIC)* 2005; 13(3): 10-13

12. **Ananworanich J.** Immunizations for persons infected with human immunodeficiency virus. Textbook on vaccines and vaccines preventable infectious diseases (Thai) by the Pediatric Infectious Disease Society of Thailand: 2005: 331-343
13. **Ananworanich J,** Hirschel B. Interrupting highly active antiretroviral therapy in patients with HIV disease. Expert Review of Anti-infective Therapy: 2005: 3 (1): 51-60
14. Pancharoen C, **Ananworanich J,** Thisyakorn U. Immunization for persons infected with human immunodeficiency virus. Current HIV Research 2004; 2:293-9
15. **Ananworanich J,** Shearer WT. Immune deficiency in metabolic diseases. In Immunologic disorders in infants and children-5th Ed, Stiehm ER editor, 2004
16. Cunningham-Rundles S, McNeely D, **Ananworanich J.** Immune response in malnutrition. In Immunologic disorders in infants and children-5th Ed, Stiehm ER. Editor, 2004
17. **Ananworanich J,** Phanuphak P, Ruxrungtham K. Immune reconstitution syndrome: When patient deteriorates after highly active antiretroviral therapy. J of Infectious Diseases and Antimicrobial Agents 2003; 20 (2): 109-118
18. Photikamchon S, **Ananworanich J,** Chantaphakul H. Novel therapies for allergic diseases. Royal College Bulletin 2002; 19 (2):20-31.
19. **Ananworanich J,** Shearer WT. Delayed-type hypersensitivity skin testing. In Manual of Clinical Laboratory Immunology-6th Ed , Rose NR editor. ASM Press, Washington, D.C. 2002
20. **Ananworanich J.** Antiretroviral therapy in children. In Pediatric AIDS (Thai)-1st Ed, Pancharoen C. editor. Chulalongkorn Publishing Co., 2002.
21. **Ananworanich J,** Shearer WT. Immune deficiencies in congenital and metabolic diseases. In Clinical Immunology: Principles and Practice-2nd Ed, Rich R. editor. Mosby International Limited, 2001
22. **Ananworanich J,** Shearer WT. Immunodeficiency: Severe combined immunodeficiency. In Encyclopedia of Life Sciences, Published online (www.els.net), 2000

โครงการวิจัยอื่นๆที่กำลังดำเนินการ

ที่	ผู้วิจัยหลัก	หัวข้อ	แหล่งทุน	ปีที่ได้	ปีที่เสร็จ
1	รศ.ดร.พญ. จินตนาถ อนันต์วรณิชย์	การศึกษาความสัมพันธ์ ระหว่างภูมิคุ้มกันแบบพื้ เซลล์และการดำเนินของ โรคเอชไอวีในเด็กที่ติดเชื้อ เอชไอวี	สถาบันวิจัยแห่งชาติ สหรัฐ	2550	2554
2	รศ.ดร.พญ. จินตนาถ อนันต์วรณิชย์	การศึกษาภูมิคุ้มกันแบบ พื้เซลล์ในเด็กที่สุขภาพ แข็งแรง	สำนักงานกองทุน สนับสนุนการวิจัย	2552	2553
3	รศ.ดร.พญ. จินตนาถ อนันต์วรณิชย์	การติดตามและรักษากลุ่ม ผู้ใหญ่ไทยที่ติดเชื้อเอชไอวี ระยะเฉียบพลัน	กรมแพทย์ทหารบก สหรัฐ	2551	2555
4	ศ.นพ.เกียรติ รักษ์รุ่งธรรม	การวิจัยโดยวิธีสุ่มที่ให้ยา แบบเปิดเผยเพื่อ เปรียบเทียบความมี ประสิทธิผลของการเริ่มให้ ยาด้านไวรัสเมื่อซีดีสี่ เท่ากับ 15 – 24 % หรือ เริ่มให้ยาด้านไวรัสเมื่อซีดี สี่ลดลงต่ำกว่า 15% ใน เด็กที่ติดเชื้อเอชไอวีและมี ภูมิต้านทานต่ำปานกลาง (โครงการวิจัย PREDICT)	สถาบันวิจัยแห่งชาติ สหรัฐ	2547	2554
5	ศ.นพ.เกียรติ รักษ์รุ่งธรรมและรศ. ดร.พญ.จินตนาถ อนันต์วรณิชย์	ผลของการเปรียบเทียบ การให้ยาด้านไวรัสแบบ ทันทีกับแบบรอในเด็กติด เชื้อเอชไอวีที่มีผลต่อ พัฒนาการทางระบบ ประสาท ในประเทศไทย และประเทศกัมพูชา	สถาบันวิจัยแห่งชาติ สหรัฐ	2550	2554

งานประจำในช่วงเวลาที่จะทำการวิจัยโดยประมาณ

1. อาจารย์พิเศษ หน่วยภูมิแพ้และภูมิคุ้มกัน ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย
2. นักวิจัย ศูนย์ประสานความร่วมมือเนเธอร์แลนด์ ออสเตรเลีย ไทย เพื่อการวิจัยด้านโรคเอดส์ (HIVNAT)
ศูนย์วิจัยโรคเอดส์ สภากาชาดไทย และหน่วยความร่วมมือเพื่อการวิจัยระหว่างภูมิภาคเอเชียตะวันออกเฉียงใต้
และฮาวาย (SEARCH)